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Introduction 
Shigella are a group of pathogenic bacteria under the Enterobacteriaceae family. They 
are gram-negative, non-motile, facultatively anaerobic bacteria which include four main 
subgroups: Shigella flexneri, Shigella boydii, Shigella sonnei, and Shigella dysenteriae. Of the 
four subgroups, S. dysenteriae is associated with the most severe outbreaks due to its high 
infection-fatality rate in low-income areas of central Asia, central America, and southeastern 
Africa. S. flexneri and S. sonnei are considered to be the most ubiquitous subgroups, and 
collectively, they are responsible for the majority of Shigella cases globally. S. boydii is the least 
common subgroup, most likely due to its specificity to the India sub-region. When considering 
the United States and other high-income countries, S. sonnei is considered to be the most 
infectious subgroup (Kotloff et al, 2018; Baker and The, 2018). Figure 1 shows that from 1990-
2014, the United States had a >3:1 ratio of S. sonnei to S. flexneri isolates. 
 
Fig. 1: The ratio of S. sonnei to S. flexneri infections isolated from 100 countries, 1990-2014. The 
darker the color, the more often S. sonnei was isolated compared to S. flexneri. The lighter the 
color, the more proportionally S. flexneri was isolated. Grey areas indicate countries where no 
data was collected (Thompson et al, 2015).  
   
 
Victims of Shigella infection often contract a form of shigellosis, a disease which 
primarily induces aggressive dysentery. Other symptoms associated with shigellosis include 
fever, abdominal cramping, vomiting, dehydration, and nutrient deficiency. In rare cases, 
shigellosis from S. flexneri can additionally cause Reiter’s syndrome (reactive arthritis) post-
infection. Shigella are predominantly transferred via fecal-oral contamination, but the bacteria 
can also be foodborne or waterborne. Recent studies have also concluded that Shigella can be 
transferred via houseflies (Kotloff et al, 2018). In the United States alone, Shigella infections 
cause approximately half a million infections, 6,000 hospitalizations, and 70 deaths annually 
(Kozryeva et al, 2016). This manuscript will compare Shigella to pathogenic Escherichia coli and 
explain how Shigella developed their own virulence mechanisms. Then, groups that are of 
particular risk to Shigella infection will be discussed, followed by an analysis of the increasing 
antibiotic resistance in Shigella found in the United States, and what those increases imply for 
the future. 
Genotypic comparison of Shigella to E. coli 
Current genomic research indicates that Shigella species originated from pathogenic 
strains of Escherichia coli. Both Shigella and pathogenic E. coli contain the virulence plasmid 
pINV, which contains coding for a unique virulence mechanism called the type 3 secretion 
system (T3SS). T3SS allows bacteria to inject effector proteins directly into the cytosol of host 
cells to illicit an array of responses (Kotloff et al, 2018). The pINV plasmid also holds sequences 
for a number of Shiga toxins shared between Shigella and E.coli. Despite these fundamental 
similarities to E. coli, however, Shigella subgroups have a number of evolutionary divergences 
that are unique. Primarily, Shigella bacteria have developed traits such as proton consumption 
systems, producing mucinases, and host antimicrobial resistance (Kotloff et al, 2018). All of 
these play an important role in Shigella survivability. Shigella also diverged from E. coli by losing 
motility, and several metabolic pathways common to E. coli are no longer present in Shigella. 
Most of these metabolic pathways are still not fully understood. Table 1 compares key 
relationships between Shigella and pathogenic E. coli. 
 
   
 
*Only in the case of S. sonnei 
Table 1: Comparison of trait presence/absence between Shigella and pathogenic E. coli. “-” 
denotes the absence of a trait, whereas “+” represents the presence of a trait. Table 
synthesized using information from another manuscript (Ud-Din and Wahid, 2014). 
Much of Shigella genome divergence can be related to the high ratio of insertion 
sequences (IS) to gene counts within Shigella chromosomes (Fig. 2). These IS are transposable 
elements able to move genetic material on chromosomes, thus causing mutations. Studies have 
proven that Shigella chromosomes can contain approximately 13-42 times more IS than those 
of pathogenic E. coli (Hawkey et al, 2019). This means that Shigella bacteria are likely to mutate 
more often than other similar bacteria, thus increasing the chance for genome divergence.  
Trait Shigella Pathogenic E. coli 
Lactose fermentation   -* + 
Salicin fermentation - + 
Motility - + 
pINV plasmid + + 
Can cause Haemolytic 
Uraemic Syndrome 
+ + 
Presence of Shiga toxins + + 
   
 
Figure 2: Box plots of five IS genes common to shown Shigella species and E. coli species 
(Hawkey et al, 2019). 
Pathogenicity of Shigella 
Research has connected Shigella pathogenicity to high in-host survivability and low 
infectious dose. Infections can be contracted after ingestion of less than 10-200 organisms, and 
symptoms usually show within 12-50 hours. Once within the human body, Shigella can survive 
stomach acid and the numerous competitive intestinal microbiota, ultimately settling on the 
mucosal layers of the ileum, colon, and rectum. The bacterial cells are phagocytized by 
Microfold cells (M-cells), allowing Shigella to inject effector proteins into the M-cells using T3SS 
(Kotloff et al, 2018). 
Although the exact mechanism is not fully understood, research indicates that the 
injection of effectors like the invasion plasmid antigen H (IpaH) family proteins ultimately 
induces the reorientation of actin polymerization, allowing Shigella to provoke intracellular 
motility. Therefore, the bacterial cells are able to hijack host cells to move and replicate in 
neighboring epithelial cells, consequently stirring inflammatory cell death and severe intestinal 
inflammation (Ashida and Sasakawa, 2016). 
Groups at risk 
Although Shigella poses a threat to everyone, there are some groups that are notably 
more susceptible than others. Transmission in these areas is mostly a result of underdeveloped 
food/water quality and under-privileged sanitation/hygiene. Therefore, it is not surprising that 
the majority of shigellosis cases arise from young children (ages 1-4) in low to middle-income 
countries. In the United States, the age trend is similar. Most shigellosis cases stem from 
children held in day-care facilities (Kotloff et al, 2018). However, a recent S. sonnei outbreak 
within a retirement community in Vermont revealed that elderly and immunocompromised 
individuals are also likely to be more susceptible (Strysko et al, 2019). People traveling from 
high-income to low/middle-income countries are another group that is more vulnerable to 
Shigella infection. Studies have shown that Shigella is one of the leading causes of diarrheal 
infection for these groups (Khalil et al, 2018). It is also worth mentioning that over the past few 
   
 
years, men who have sex with other men (MSM) have shown an increasing number of Shigella 
infections. Several case studies have identified instances where Shigella have been passed 
sexually between MSM (Kennedy et al, 2017; Bowen et al, 2016; Heiman et al, 2014). The 
spread of Shigella infection via travel and MSM are also proven to be large contributors to the 
growing antibiotic resistance in Shigella, particularly S. sonnei. 
Antibiotic resistance in Shigella 
The use of antibiotics has been the primary solution for Shigella infections for many 
years, but as a result, drug resistance is an ever-increasing issue. Studies on antibiotic resistance 
in Shigella all show trends of increasing resistance to commonly used antibiotic treatments. In 
the mid-late 1900s, streptomycin, tetracycline, and trimethoprim-sulfamethoxazole were some 
of the most prescribed antibiotics in the United states to reduce symptoms and pathogen 
shedding from Shigella species. However, by the 21st century, the majority of Shigella isolates 
showed resistance to all these (Howie et al, 2010). Afterward, ampicillin and co-trimoxazole 
became the primary antibiotics used to treat Shigella cases. Similarly, Shigella quickly 
developed resistance to these drugs. Nalidixic acid and fluoroquinolones were introduced to 
replace previous treatments, but Shigella species acquired resistance to these antibiotics as 
well (Puzari et al, 2018). In 2006, a study tested 1,604 Shigella isolates for antibiotic resistance 
and concluded that all of them were susceptible to ceftriaxone (Sivapalasingam et al, 2006). 
More recently however, studies have found Shigella isolates with resistance to ceftriaxone 
(Puzari et al, 2018).  
As of now, ciprofloxacin is recommended as the primary antibiotic used to treat Shigella 
in adults and children. Unfortunately, studies have shown an increasing resistance to this 
antibiotic as well (Fig. 3). In 2017, the CDC issued a health advisory urging that the use of 
antibiotics for Shigellosis be reserved for only the most serious cases due to the noticeable 
increase in ciprofloxacin resistance. As Shigella continue to develop resistance to our best 
treatment methods, it is imperative that the mechanisms and origins of resistance in Shigella be 
further identified and understood.  
 
   
 
 
Figure 3: Data was collected and synthesized from the National Antimicrobial Resistance 
Monitoring System (NARMS) 
As mentioned previously, much of the growing antibiotic resistance in Shigella 
correllates with the high amount of IS present on Shigella chromosomes, the transmission of 
bacterial strains from travel, and the transmission via MSM. Antibiotic resistance in Shigella and 
other pathogenic bacteria resides within specific genes. An antibiotic resistance gene codes for 
mechanisms that ultimately give resistance against a specific antibiotic, and these genes are 
able to be passed between different strains of Shigella. As people travel between high to 
low/middle-income countries, antibiotic resistance genes are able to be passed amongst 
Shigella and spread around the world. Table 1 lists antibiotic resistance in S. sonnei isolates 
collected from the United States and how resistance relates with travel (Abelman et al, 2019). 
Studies also have concluded that MSM can not only transfer Shigella to one another sexually, 
but MSM also may be more susceptible to multi-drug resistant strains of Shigella. It is known 
that HIV-positive men have a higher potential for co-infections with Shigella as well as 





















% Resistance to Ciprofloxacin in Shigella, Salmonella typhi, and 
E. coli O157 isolates from the United States, 2000-2015
Shigella Salmonella typhi Escherichia coli
   
 
This raised risk of infection combined with sexual interaction increases the transmission of 
antibiotic resistance genes among strains of S. sonnei and S. flexneri (Baker et al, 2015).  
 
Table 2: All isolates were taken from the Pennsylvania Department of Health. Travel History 
highlights where the Shigella isolate originated from. “None” values in this column imply that 
the person from which this isolate was collected from did not report any travel outside of the 
U.S. Isolates that showed resistance to ciprofloxacin or azithromycin are highlighted. 
Antimicrobial Resistance (AMR) abbreviations represent as follows: streptomycin (STR), 
gentamicin (GEN), ampicillin (AMP), amoxicillin (AMC), cefoxitin (FOX), trimethoprim-
sulfamethoxazole (SXT), sulfamethoxazole (SMX), tetracycline (TET), chloramphenicol (CHL), 
PSU-ID Travel history Year of isolation AMR profile 
SS-27 None 2010 STR, AMP, SXT, SMX, TET 
SS-2 None 2011 STR, AMP, AMC, FOX, TET 
SS-28 None 2011 STR, AMP, AMC, FOX 
SS-29 None 2011 STR, AMP, AMX, FOX 
SS-32 None 2012 AMP, AMC, SXT, CHL, SMX, TET 
SS-36 None 2012 STR, SXT, CIP, NAL, SMX, TET 
SS-39 None 2013 STR, SXT, CIP, NAL, SMX, TET 
SS-40 None 2013 STR, AMP, SXT, SMX, TET 
SS-3 None 2013 GEN, STR, SXT, SMX, TET, AZM 
SS-4 None 2013 STR, SXT, SMX, TET 
SS-5 None 2014 STR, AMP, SXT, SMX, TET, AZM 
SS-43 Mexico 2014 STR, SXT, NAL, SMX, TET 
SS-38 Dominican 
Republic 
2013 STR, AMP, SXT, SMX, TET 
SS-42 Dominican 
Republic 
2014 STR, SXT, NAL, SMX, TET 
SS-37 Haiti 2013 STR, AMP, SXT, SMX, TET 
SS-26 Jamaica 2010 STR, SXT, NAL, SMX, TET 
SS-30 Peru 2012 AMP, AMC, SXT, CHL, SMX, TET 
SS-31 Peru 2012 AMP, AMC, SXT, CHL, SMX, TET 
SS-21 India 2009 STR, SXT, NAL, SMX, TET 
SS-24 India 2010 STR, SXT, CIP, NAL, SMX, TET 
SS-35 India 2012 STR, SXT, CIP, NAL, SMX, TET 
SS-23 Nepal 2009 STR, SXT, CIP, NAL, SMX, TET 
   
 
ciproflaxin (CIP), nalidixic acid (NAL), and azithromycin (AZM). Table modified from (Abelman et 
al, 2019). 
Conclusion 
 Shigella is a widespread, highly pathogenic bacteria that causes many infections and 
deaths worldwide. In the United States and other high-income countries, S. sonnei is the most 
concerning subgroup, due to its high drug resistance. Over several years, studies have indicated 
that Shigella is highly adaptable. Shigella continues to quickly develop antibiotic resistance to 
commonly used antibiotics  in the United States. Some of the bacteria’s fast response to new 
antibiotics can be connected back to the high amounts of IS sequences present within Shigella 
chromosomes. These sequences allow the bacteria to undergo rapid mutations to develop 
antibiotic resistant genes. As multi-drug resistance continues to gain more attention, 
researchers are beginning to develop new solutions to reduce the need for so many antibiotics. 
Using genome sequencing, scientists are now able to observe the entire genome of a particular 
strain of Shigella to identify the antibiotic resistance genes present. Identification of these 
genomes will allow for more specific treatment of Shigella infections, ultimately increasing the 
number of successful treatments while also slowing the rate of antibiotic resistance 
development. However, the exact mechanism of these antibiotic resistance genes needs to be 
better understood before this form of treatment could be viable. These sequences contain 
unique, often complex mechanisms for a particular resistance gene, and it will take time to fully 
understand them at a level which treatment could be effectively prescribed. Additionally, new 
mechanisms will inevitably continue to develop in Shigella species, so researching these 
mechanisms would essentially be a never-ceasing process. Another treatment option highlights 
taking preventative measures via vaccination. Tests have already indicated that O-
polysaccharide conjugate vaccines reduce the severity of Shigella infections (Kotloff et al, 
2018). However, it is important to note that these vaccinations were serotype specific. Until a 
vaccine providing cross-species immunity is established, it will be difficult for vaccination to 
keep up with the rate of change in strains of S. sonnei and S. flexneri. Until further treatment 
methods can be bolstered, it is important to moderate Shigella infections by practicing good 
hygiene.
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